Background Nintedanib is generally safe and well tolerated and can improve prognosis in
patients with various interstitial lung diseases (ILDs). Appropriate management of adverse …

Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is
recognized as an adverse event during nintedanib treatment, and is a common complication …

Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …

Nintedanib, an intracellular inhibitor targeting multiple tyrosine kinases, has emerged as a
standard treatment for various fibrotic lung diseases. Despite its efficacy, side effects such as …

Background The tyrosine kinase inhibitor nintedanib reduces the rate of decline in forced
vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF), other chronic …

Background: We have often encountered adverse events requiring dose reduction and/or
discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Objectives: The …

Background Nintedanib is now widely used to treat interstitial lung disease (ILD). Adverse
events, which occur in not a few patients, make it difficult to continue nintedanib treatment …

Methods Retrospective study of patients treated with Nintedanib on a Named Individual
Patient Supply (NIPS) by Boehringer UK for PFILD at a tertiary referral ILD specialist centre …

Background In the INBUILD trial in patients with progressive fibrosing interstitial lung
diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity compared …

Background The primary analysis of the INBUILD trial showed that in subjects with
progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in …